DiPT Stats - Substance Search

Receptor Profile

Receptor Actions

Agonists

5-HT2A receptor agonist (full)

5-HT2B receptor agonist (full)

5-HT2C receptor agonist (full)

Inhibitors

Serotonin reuptake inhibitor (weak)

History & Culture

1959–1997

DiPT was first characterized in the scientific literature by R.B. Barlow and colleagues in 1959. Alexander Shulgin began investigating the compound's effects in humans during the mid-1970s, with his initial findings dating to 1974 and basic properties disclosed in 1976. Shulgin published more detailed characterizations of DiPT alongside 5-MeO-DiPT in a 1980 journal article, followed by additional publications throughout the 1980s. A comprehensive synthesis and collection of human use reports appeared in Shulgin's 1997 book TiHKAL (Tryptamines I Have Known And Loved), which brought the compound to wider attention within the psychedelic research community. DiPT was subsequently encountered as a novel designer drug in Europe by 2005 and has since circulated online as a research chemical.

DiPT's unusual property of producing primarily auditory rather than visual effects has generated interest for potential neurological research applications. Shulgin speculated that the compound might serve as a valuable tool for studying the auditory system, potentially helping to locate the pitch-processing center of the brain if combined with imaging techniques such as positron emission tomography. A small study was conducted administering DiPT to two individuals with perfect pitch to investigate whether any systematic relationship existed between a note's actual pitch and the perceived pitch under the drug's influence. The results revealed no meaningful correlation, though they reinforced observations that the pitch decrease produced by DiPT is not linear and involves genuine harmonic distortion rather than a simple uniform pitch shift.

Subjective Effects

Sensory

Auditory

Enhancements
Distortions
Hallucinations

Forked from Subjective Effect Documentation work by Josie Kins, August 2016. Via dose.wiki (CC0).

Toxicity

PsychonautWiki

The toxicity and long-term health effects of recreational DiPT do not seem to have been studied in any scientific context and the exact toxic dose is unknown. This is because DiPT is a research chemical with very little history of human usage. Anecdotal reports from those who have tried DiPT suggests that there are no negative health effects attributed to simply trying the drug by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption. It is strongly recommended that one use harm reduction practices when using this drug.

Addiction & dependence

DiPT is not habit-forming and the desire to use it can actually decrease with use. It is most often self-regulating. Tolerance to the effects of DiPT is built almost immediately after ingestion.

Effect Profile

Curated + 70 Reports

Psychedelic 6.5

Strong visuals and auditory effects with strong body load, mild headspace

Visual Intensity×3

10102.4

Headspace Depth×3

45.01.6

Auditory Effects×1

10106.2

Body Load / Somatic Effects×1

107.13.5

Catalog Erowid BlueLight

Based on reports from:

Effect Index Exactly as Advertised — nervewing Effect Index Altered Sounds, as Advertised — nervewing TiHKAL TiHKAL #4: DIPT Bluelight Big & Dandy Thread Erowid Experience Reports PsychonautWiki DiPT

Duration Timeline

Bluelight

Onset Comeup Peak Offset After Effects

Oral

19 minutes - 1.0 hours

30 minutes - 1.0 hours

2-4 hours

24 hours

Total: 3-5 hours

Smoked

6-12 minutes

12-24 hours

Total: 15-60 minutes hours

Tolerance & Pharmacokinetics

drugs.wiki

Half-Life

Not well-established in humans; functional effects typically span several hours.

Addiction Potential

Low; not considered habit-forming, with little evidence of compulsive use.

Tolerance Decay

Full tolerance 6h Half tolerance 7d Baseline ~14d

Rapid tolerance typical of serotonergic psychedelics; spacing doses by 1–2 weeks minimizes attenuation. Model values are heuristic from community reports (anecdotal).

Cross-Tolerances

Psilocybin/Psilocin

DMT/MET/MiPT/DPT

Lysergamides (e.g., LSD/AL-LAD)

Experience Report Analysis

Erowid BlueLight

76 Reports

46 Single-substance

1999–2025 Date Range

17 With Age Data

22 Effects Detected

Demographics

Gender Distribution

Age Distribution

Reports Over Time

Effect Analysis

Erowid + Bluelight

Effects aggregated from 70 experience reports (46 single-substance Erowid + 24 Bluelight)

70 Reports

87 Effects Detected

36 Positive

28 Adverse

23 Neutral

Effect Sentiment Distribution

Confidence Distribution

Each bar is the share of reports mentioning the effect; its whisker, and the band on the rows below, is the 95% interval: where the share could plausibly be with other reports of the same kind.

Positive Effects 36

Music Enhancement 69.6% 70%

Visual Distortions 48.6% 75%

Body High 37.1% 79%

Music Distortion 25.0% 90%

Euphoria 21.4% 87%

Color Enhancement 20.0% 79%

Stimulation 18.5% 73%

Closed-Eye Visuals 17.2% 84%

Joy 16.7% 79%

Introspection 12.8% 71%

Visual Trails 12.5% 72%

Entity Imagery 12.5% 85%

Bliss 12.5% 78%

Libido Enhancement 12.5% 73%

Contentment 12.5% 85%

Tactile Enhancement 11.4% 80%

Open-Eye Visuals 8.7% 70%

Empathy 8.6% 90%

Awe 8.3% 70%

Ego Inflation 8.3% 70%

Adverse Effects 28

Nausea 34.3% 88%

Confusion 18.5% 78%

Anxiety 17.1% 80%

Vomiting 16.7% 91%

Tinnitus 16.7% 88%

Depersonalization 16.7% 76%

Restlessness 12.5% 78%

Dizziness 12.5% 92%

Motor Suppression 12.5% 85%

Disrupted Sleep Architecture 12.5% 75%

Pupil Dilation 10.0% 76%

Headache 8.3% 78%

Body Load 8.3% 80%

Insomnia 8.3% 80%

Double Vision 8.3% 90%

Blurred Vision 8.3% 85%

Field Narrowing 8.3% 80%

Panic 8.3% 85%

Fear 8.3% 85%

Memory Suppression 8.3% 90%

Show 8 more adverse effects

Body Temperature Change 8.3% 75%

Dry Mouth 8.3% 70%

Stomach Cramps 8.3% 62%

Sweating 7.1% 80%

Muscle Tension 6.5% 70%

Auditory Suppression 4.2% 80%

Directional Hearing Distortion 4.2% 80%

Irritability 4.2% 80%

Show 23 neutral or unclassified mentions

Auditory Effects 80.0%

Pitch Shifting 66.7%

Surface Breathing 29.2%

Pressure 20.8%

Time Dilation 12.5%

Thought Deceleration 12.5%

Ego Dissolution 10.0%

Focus Suppression 8.3%

Tingling 8.3%

Sedation 7.2%

Time Distortion 6.5%

Dissociation 6.5%

Peripheral Imagery 4.2%

Thought Acceleration 4.2%

Numbness 4.2%

Thought Disorganization 4.2%

Visual Drifting 4.2%

Thought Loops 4.2%

Internal Auditory Hallucination 4.2%

Frequent Urination 4.2%

Spatial Distortion 4.2%

Distractibility 4.2%

Volume Distortion 4.2%

Also reported in combinations. In the 30 DiPT reports where another drug was taken too, 5 (16.7%) mention hospital, emergency services or an overdose, 1 (3.3%) a seizure and 0 (0.0%) psychosis. In the 46 single-substance reports: 2.2%, 2.2% and 0.0%. These are not in the figures above: they cannot be put down to DiPT alone, and a mention is not always something that happened to the writer.

Dosage Distribution

Dose distribution from experience reports, one dose per report (the first listed). Doses above Q3 + 3×IQR, far above what people typically take, are left out of the median and range and listed under each route: most are real heavy doses or overdoses, not mistakes.

Median: 50.0 mg IQR: 30.5–74.8 mg n=30

1 report gave a dose above the typical range (250 mg), so it is not in the figures above. Listing a dose here does not mean it is safe.

Show the report

250 mg · another drug taken too

Real-World Dose Distribution

Erowid

From 74 of 77 recorded dose entries: those that state a weight (mg, g or µg), in routes with at least five of them. Values above Q3 + 3×IQR, far above what people typically take, are left out; they can include real heavy doses and overdoses, not only mistakes.

Oral (n=56)

Median: 47.5mg 25th: 25.0mg 75th: 70.0mg 90th: 100.0mg

Insufflated (n=11)

Median: 15.0mg 25th: 5.0mg 75th: 100.0mg 90th: 100.0mg

Smoked (n=6)

Median: 14.75mg 25th: 10.5mg 75th: 19.38mg 90th: 22.5mg

Common Combinations

Most co-occurring substances, as a share of all 76 reports filed under DiPT; whiskers are 95% intervals

Form / Preparation

Most common forms and preparations, as a share of the 50 reports that give one; whiskers are 95% intervals

Body-Weight Dosing

Dose per kg of body weight, one dose per report (the first listed), from reports giving a weight of 30–250 kg. Doses above Q3 + 3×IQR, far above what people typically take, are left out of the median and range and listed under each route.

Median: 0.552 mg/kg IQR: 0.408–0.987 mg/kg n=28

1 report gave a dose above the typical range (3.243 mg/kg), so it is not in the figures above. Listing a dose here does not mean it is safe.

Show the report

3.243 mg/kg · another drug taken too

Redose Patterns

Redosing behavior across 52 reports

7.7% Redosed

1.1 Avg Doses

45m Median Interval

Legal Status

Country	Status	Notes
Germany	NpSG (Controlled)	Controlled under the Neue-psychoaktive-Stoffe-Gesetz (New Psychoactive Substances Act) as of July 18, 2019. Production, import with intent to distribute, administration to others, and trading are punishable offenses. Possession is prohibited but not subject to criminal penalties.
Japan	Designated Substance	Controlled as a Designated Substance (Shitei-Yakubutsu) under the Pharmaceutical Affairs Law. Both possession and sale are prohibited.
Latvia	Schedule I	Listed as a Schedule I controlled substance under national drug control legislation.
New Zealand	Class C	Classified as a Class C controlled substance due to its structural relationship to DMT, which is covered under analogue provisions in New Zealand drug law.
Sweden	Proposed for scheduling	Sweden's public health agency recommended classifying DiPT as a hazardous substance on May 15, 2019. Current legal status may have changed following this recommendation.
Switzerland	Uncontrolled	Not listed under Buchstabe A, B, C, or D of controlled substances legislation. May be considered legal to possess, though sale for human consumption could still raise regulatory issues.
United Kingdom	Class A	Controlled as a Class A substance under the Misuse of Drugs Act 1971 due to the tryptamine catch-all clause, which covers structurally related compounds.
United States	Unscheduled (Federal Analogue Act may apply)	Federally unscheduled, though it may be considered an analogue of DET or 5-MeO-DiPT under the Controlled Substances Act. Sales for human consumption or possession with intent to ingest could potentially be prosecuted under the Federal Analogue Act. Specifically listed as Schedule I in Florida and Louisiana (since June 2013).

Harm Reduction

drugs.wiki

DiPT is notable for its unique auditory distortions—often downward pitch-shifting and nonlinear harmonic distortion—while visual changes are usually mild compared with other psychedelics. The altered pitch/timbre can persist into the next day in some users; to protect hearing and reduce disorientation, avoid loud venues, high headphone volumes, and tasks requiring accurate sound localization or timing (e.g., driving). Onset can be subtle; avoid redosing during the first 2–3 hours as tolerance rises quickly and effects may surge later. People with seizure disorders, on lithium, or taking serotonergic drugs (SSRIs/SNRIs/TCAs, tramadol, DXM, 5-HTP) should avoid DiPT due to seizure or serotonin-toxicity concerns. Set/setting and a sober sitter are recommended—auditory scene distortions can impair communication and situational awareness. Use drug checking: reagent tests help confirm a tryptamine (e.g., Ehrlich), but laboratory confirmation via GC/MS (e.g., DrugsData) best verifies identity. Data on non‑oral ROAs are sparse; oral is the best-characterized and most predictable route.

DiPT Stats & Data

Receptor Profile

Receptor Actions

History & Culture

1959–1997

Subjective Effects

Sensory

Toxicity

Addiction & dependence

Effect Profile

Duration Timeline

Tolerance & Pharmacokinetics

Tolerance Decay

Cross-Tolerances

Experience Report Analysis

Demographics

Gender Distribution

Age Distribution

Reports Over Time

Effect Analysis

Effect Sentiment Distribution

Confidence Distribution

Positive Effects 36

Adverse Effects 28

Dosage Distribution

Real-World Dose Distribution

Oral (n=56)

Insufflated (n=11)

Smoked (n=6)

Common Combinations

Form / Preparation

Body-Weight Dosing

Redose Patterns

Legal Status

Harm Reduction

References

Data Sources

Cited References

Additional references